

DanioLabs Ltd

[View the current DanioLabs Ltd Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/21676-DanioLabs+Ltd.html)

(<http://www.bioportfolio.com/biocorporate/21676-DanioLabs+Ltd.html>)

Contact Details:

**7330 Cambridge Research Park
Cambridge
Cambridgeshire
CB5 9TN
United Kingdom**

Tel: 44(0)1223 706460

Fax:

Email: info@daniolabs.com

DanioLabs (Cambridge UK) is a therapeutics company that has two primary business streams:

Internal R&D investigating new uses for established drugs (Reprofiling)

Phenotypic evaluation of compounds for other organisations, either for activity effects, or for preclinical safety pharmacology

As part of our approach, we use zebrafish as a key enabling technology. zebrafish as an experimental species provides significant benefits in the drug discovery process. They produce tiny, transparent offspring, that share some significant physiological and pharmacological similarities to humans, not least that they are vertebrates. Their size allows them to be used to evaluate the effects of compounds in human disease models in 96 well plate format. Therefore, medium throughput, high content in vivo assays are possible.

Recent Publications by DanioLabs Ltd:



- [Non-associative learning in larval zebrafish.](#)

*Habituation, where a response is reduced when exposed to a continuous...*2nd August, 2008

DanioLabs Ltd (a wholly owned subsidiary of VASTox plc), Unit 7330,- Neuropsychopharmacology. 2008 Apr;33(5):1206-15. Epub 2007 Jun 20. ([DOI Direct Link](#))

- [GBR12909 possesses anticonvulsant activity in zebrafish and rodent models of generalized epilepsy but cardiac ion channel effects limit its clinical utility.](#)

*BACKGROUND/AIMS: GBR12909 has been reported to possess anticonvulsant...*6th December, 2007

DanioLabs- Pharmacology. 2007;79(4):250-8. Epub 2007 Apr 27. ([DOI Direct Link](#))

- [Zebrafish offer the potential for a primary screen to identify a wide variety of potential anticonvulsants.](#)

*The search for novel anticonvulsants requires appropriate model systems in...*19th August, 2007

DanioLabs Ltd., 7330 Cambridge Research Park, Cambridge CB25 9TN, UK.- Epilepsy Res. 2007 Jun;75(1):18-28. Epub 2007 May 7. ([DOI Direct Link](#))

- [A rapid, high content, in vivo model of glucocorticoid-induced osteoporosis.](#)
*Glucocorticoid-induced osteoporosis (GIOP) is a major clinical problem...*9th December, 2006
DanioLabs Ltd, Cambridge, UK.- *Biotechnol J.* 2006 Jun;1(6):651-5. ([DOI Direct Link](#))
- [High-throughput in vivo screening for bone anabolic compounds with zebrafish.](#)
*Osteoporosis and diseases of bone loss are a major public health problem...*19th May, 2006
DanioLabs- *J Biomol Screen.* 2005 Dec;10(8):823-31. Epub 2005 Oct 18. ([DOI Direct Link](#))
- [Zebrafish as a pharmacological tool: the how, why and when.](#)
*Zebrafish combine the relevance of a vertebrate with the scalability of an...*1st April, 2005
DanioLabs Ltd, 7330 Cambridge Research Park, Cambridge CB5 9TN, UK.- *Curr Opin Pharmacol.* 2004 Oct;4(5):504-12. ([DOI Direct Link](#))

Press Releases on DanioLabs Ltd:

DANIOLABS SCREENING COMBINATION PRODUCTS FOR COMBINATORX IN INFLAMMATORY	1st October, 2003	Daniolabs	<i>DANIOLABS SCREENING COMBINATION PRODUCTS FOR COMBINATORX IN INFLAMMATORY BOWEL DISEASE THE EFFECTS OF MODULATING</i> <i>DanioLabs announce revenue generating deal with KS Biomedix 28th August 2003 DanioLabs Ltd, the UK based drug discovery company which</i>
DanioLabs announce revenue generating deal with KS Biomedix	1st August, 2003	Daniolabs	<i>Catalyst BioMedica fund DanioLabs in the search for novel treatments for neurological and ophthalmic disorders. 6th</i>
Catalyst BioMedica fund DanioLabs in the search for novel treatments for	1st November, 2002	Daniolabs	<i>DANIOLABS RAISES £850k IN SEED FUNDING TO ACCELERATE ITS DRUG DISCOVERY PROCESS 10th July 2002. DanioLabs</i>
DANIOLABS RAISES £850k IN SEED FUNDING TO ACCELERATE ITS DRUG	1st October, 2001	Daniolabs	<i>DanioLabs Announces BBSRC Funding for Multiple Sclerosis Research Programme June 24th 2005: DanioLabs Ltd</i>
DanioLabs Announces BBSRC Funding for Multiple Sclerosis Research	1st January, 1970	Daniolabs	

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

